A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
136actual
Sites
21
Countries
Canada, China, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-28 | actual | When the study began enrolling |
| Primary completion | 2024-12-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-12 | estimated | The whole study's end, after follow-up |
| First posted | 2021-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non-Small-Cell Lung
- Gastric Cancer
- Gastroesophageal Junction Cancer
Intervention
- Drug: AZD7789
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE)
measured From time of Informed Consent to 90 days post last dose of study intervention
Number of participants with dose-limiting toxicity (DLT), as defined in the protoocol
measured From the first patient until the end of the dose escalation period; approximately 18 months.
Preliminary anti-tumour activity of AZD7789
measured From first participant until last participant assessment; a duration of approximately 4 years. Disease assessments will be performed until progression or initiation of another anticancer therapy.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed